XML 107 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Recognition and Accounts Receivable - Additional Information (Detail)
€ in Millions
 1 Months Ended 12 Months Ended
Mar. 31, 2022
Apr. 30, 2021
Apr. 30, 2020
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
USD ($)
Dec. 31, 2020
EUR (€)
Revenue Recognition And Accounts Receivable [Line Items]                  
Marketing service fees       $ 55,276,000   $ 54,925,000   $ 53,475,000  
Cost of sales       123,544,000   114,914,000   101,889,000  
Sale of receivables       9,600,000 € 9.2 9,900,000 € 8.4 9,600,000 € 8.3
Related fees recorded as interest expense       300,000   200,000   300,000  
CARES Act of 2020 funds received     $ 13,900,000 (4,791,000)   (9,060,000)   13,851,000  
Medicare recoupment 0.50 0.25              
Contract liability, total           4,791,000   13,851,000  
Other Contract Assets [Member]                  
Revenue Recognition And Accounts Receivable [Line Items]                  
Other contract assets impairment       0   0      
Other Long-Term Assets [Member]                  
Revenue Recognition And Accounts Receivable [Line Items]                  
Other contract assets       1,100,000   1,400,000      
Shipping and Handling Costs [Member]                  
Revenue Recognition And Accounts Receivable [Line Items]                  
Cost of sales       4,200,000   $ 3,500,000   $ 2,400,000  
Biologics [Member]                  
Revenue Recognition And Accounts Receivable [Line Items]                  
Marketing service fees       $ 55,300,000          
Marketing service fee as percentage of segment revenues       98.00% 98.00%